ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Structural and microvascular retinal changes in tamoxifen users assessed by optical coherence tomography and OCT angiography.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate subclinical retinal structural, microvascular, and outer retinal reflectivity changes in women receiving tamoxifen therapy for at least 12 months without clinically apparent retinopathy.
methodsA total of 48 eyes from 48 women who had been receiving tamoxifen therapy for at least 12 months and 52 eyes from 52 age-matched healthy female controls were included in the study. Only the right eye of each participant was analyzed to avoid inter-eye correlation. All participants underwent comprehensive ophthalmic examination, swept-source optical coherence tomography (OCT), OCT angiography (OCTA), and quantitative outer retinal reflectivity analysis using ImageJ. Retinal thickness, choroidal thickness, and OCTA-derived vessel density parameters were compared between groups. Absolute and RPE-normalized reflectivity values of the retinal pigment epithelium (RPE), ellipsoid zone (EZ), and external limiting membrane (ELM) were quantified using standardized vertical line-profile analysis.
resultsThe mean age was 45.9 ± 5.4 years in the tamoxifen group and 46.6 ± 4.7 years in the control group. Retinal thickness parameters, choroidal thickness, and OCTA-derived vessel density metrics of the superficial and deep capillary plexuses and choriocapillaris were comparable between tamoxifen users and controls (all p > 0.05). Mean and central RPE reflectivity were significantly higher in the tamoxifen group than in controls (RPEav, p = 0.037; RPEc, p = 0.003), whereas EZ and ELM reflectivity values and all RPE-normalized relative reflectivity indices did not differ significantly between groups. A localized increase in outer retinal vessel density was observed in the superior sector in tamoxifen users, without corresponding widespread microvascular alterations. No significant correlations were found between duration of tamoxifen exposure and OCT, OCTA, or reflectivity parameters.
conclusionTamoxifen therapy for at least 12 months is associated with selective increases in RPE reflectivity despite preserved retinal structure and microvasculature. Quantitative reflectivity analysis may serve as a sensitive, noninvasive marker for early, subclinical retinal stress preceding clinically apparent tamoxifen retinopathy.
Indexed as
Identifiers
42507182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.